Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
This timeframe allows you to complete necessary bloodwork, receive results, consult with your provider, and establish the lifestyle habits that support optimal results
Common applications include: Obesity and Body-Weight Regulation Models : Studying how chronic exposure to AOD 9604 affects body weight, fat, and energy use in obese rodents, often using calorimetry (measuring energy expenditure) and body fat measurements
Marine collagen is higher in Type I
Am I suitable for Vitamin B12 injections, how do I know if I have a Vitamin B12 deficiency
Cellular energy & mitochondrial function studies
